Farmas USA

Ah, en ese caso lo siento, lástima no haber mantenido las coal, si reculan algo a por ellas de nuevo. Ánimo.
No me extrañaría nada ver el jdst bastante más arriba.

A ver si el oro sigue bajando y recupero. Gracias

Segun la press release de Septiembre de los datos preeliminares

http://investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=871862

"...Based on projections derived from the interim analysis, Threshold is revising its guidance on timing for the number of events (deaths) required for the primary efficacy analysis. Previously, the Company projected the pre-specified number of events (n=434) would occur around the middle of 2015; the revised projections suggest the requisite events will occur in the latter half of 2015 ..."

 Es decir, a partir de verano 2015.

THLD

DVAX
RS 10/1
Lunes abrirá a 15.90 usd
Tiene cash suficiente pero pasará de 262 millones de acciones a 26 millones por tanto sin lugar a dudas que a este RS le siga una brutal dilución, pero he dicho se supone
Ya en after cayendo

carne de corto
Anaramos se apunta fijo ja,ja

NVAX

Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014
GAITHERSBURG, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that representatives of Novavax, along with a number of its research collaborators, will be making multiple oral presentations and poster presentations related to Novavax' RSV F-protein nanoparticle vaccine candidate (RSV F Vaccine) at the 9th International Respiratory Syncytial Virus Symposium to be held November 9 – 13, 2014 in Stellenbosch, South Africa.

Poster, presentation titles, and presenters are listed below:

"Maternal Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine Leads to Transplacental Transfer of High Affinity Functional Antibodies in Infants."
Robert C. Welliver, M.D., Professor of Pediatrics and Section Chief, The University of Oklahoma Health Sciences Center

"Placental Transfer of Anti-RSV F Maternal Antibody in Rabbits and Guinea Pigs Immunized with an RSV F Nanoparticle Vaccine Co-administered with Aluminum Phosphate."
Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc.

"A Phase II Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Nanoparticle Vaccine with Aluminum, in Healthy Women of Child-bearing Age."
Nigel Thomas, Ph.D., Vice President, Clinical Operations, Novavax, Inc.

"Immunogenicity of the RSV F Nanoparticle Vaccine and Induction of Palivizumab Competing Antibodies: Review of Immunogenicity Data and Consideration of the Clinical Relevance."
Gregory Glenn, M.D., Senior Vice President, Research and Development, Novavax, Inc.

"Cotton Rats Vaccinated with RSV F-Protein Nanoparticle Vaccine are Protected from Infection with RSV Wild Type and Palivizumab Escape Mutant Virus."
Pedro Piedra, M.D., Professor of Molecular Virology and Microbiology, Baylor College of Medicine
About RSV

RSV is a widespread disease that causes infections of the lower respiratory tract. While RSV affects individuals of all ages, it acutely impacts infants, the elderly, young children and others with compromised immune systems. RSV is the number one cause of hospitalization in infants ages 0 to 12 months in the U.S. and is a significant cause of infant morbidity and mortality globally. Current estimates indicate that RSV is responsible for over 30 million new acute lower respiratory infection episodes and between 150,000 and 200,000 deaths in children under five years old. In the U.S., nearly all children become infected with RSV before they are two years old; it has been associated with 20% of hospitalizations and 15% of office visits for acute respiratory infection in young children. The World Health Organization (WHO) estimates that the global disease burden for RSV is 64 million cases. Because there is no approved prophylactic vaccine, an RSV vaccine has the potential to protect millions of patients from this far-reaching unmet medical need.

NVAX

Estamos de vuelta con el tema MERS. Si esto saliera y se solicitara una vacuna, aquí si que estamos destacados

http://www.npr.org/blogs/health/2014/11/07/361219361/how-a-tilt-toward-safety-stopped-a-scientists-virus-research

http://www.arabnews.com/saudi-arabia/news/656286